In this application We provide compounds useful for the treatment of HBV infection in a subject in need of such Pharmaceutical compositions, and Methods for inhibiting,Suppress or prevent infection by HBV in the subject.Claim 1: a compound of the formula (1) or a pharmaceutically acceptable Salt of this, where a is n or C (H) r¹ c₁₋₆ is H, alkyl, c₁₋₆ alquenilo c₁₋₆ - alkyl -, or - Oh R² in each caseIs selected independently of - Oh, c₁₋₆ alkyl, Halo, c₁₋₆ - alquileno c₀₋₆ - alkyl, cycloalkyl c₀₋₆ - c₃₋₆ -, alkyl - heterocicloalquilo c₂₋₆, c₀₋₆ - alkyl or⁶, c₀₋₆ N - alkyl (r⁷) ₂, c₀₋₆ - alkyl sr⁸,C₀₋₆ - alkyl - S (o) r⁸, c₀₋₆ - alkyl - S (o) ₂r⁸ c₀₋₆ alkyl, - C (o) - alkyl c₀₋₆ or⁹, OC (OR) r⁹, OC (c₀₋₆ - alkyl or alkyl) - c₀₋₆ r⁹, OC (o) n (₂, r⁷) and c₀₋₆ - alkyl - C (o) n (₂ r⁷), where the alkyl, cycloalkyl,And heterocicloalquilo optionally replaced with 1, 2, or 3 groups, each selected independently of - Oh and r³ Halo in each case is selected regardless of Halo, - Oh,C₁₋₆ c₁₋₆ haloalquilo alkyl -, -, - or - c₁₋₆ alkyl and alkyl c₁₋₆ - Oh r⁴ is selected (crᵃrᵇ) ₚ - c₁₋₉ - (heteroaryl, aryl c₆₋₁₂ ₚ crᵃrᵇ) - - (ₚ crᵃrᵇ) - and (- c₃₋₇ cycloalkyl, crᵃrᵇ) ₚ - c₂₋₆ - heterocicloalquilo,Where the cycloalkyl, aryl, heteroaryl, and optionally heterocicloalquilo are replaced with 1, 2, 3, or 4 groups, each independently selected from - Oh, Halo, - CN, - sf₅, c₁₋₆ alkyl,Haloalquilo c₁₋₆ -, - or - c₁₋₆ alkyl and alkyl c₁₋₆ - Oh r⁵ c₁₋₆ is selected from h, alkyl, alkyl and c₁₋₆ - Oh r⁶ c₁₋₆ is selected from h, alkyl, c₁₋₆ - haloalquilo, c₁₋₆ - alquenilo,C₀₋₆ - alkyl and cycloalkyl - c₃₋₆ r⁷ c₁₋₆ is selected from h, alkyl, c₁₋₆ - haloalquilo, c₁₋₆ - or¹⁰ alkyl, - C (o) c₁₋₆ alkyl, - C (o) c₁₋₆ haloalquilo -, - C (o) - or¹⁰ c₁₋₆ alkyl, - C (o) c₁₋₆ - alkyl - NS,- c₃₋₇ cycloalkyl C (o) -, - C (o) o - c₁₋₆ alkyl, - C (o) o - c₁₋₆ haloalquilo -, - C (o) o - c₃₋₇ cycloalkyl -, - C (o) n (₂, r¹⁰) - S (o) ₂c₁₋₆ alkyl,(o) - S - S - haloalquilo ₂c₁₋₆ and (OR) ₂c₃₋₇ cycloalkyl - or whe
